The Institute for Experimental Cellular Therapy is focused on the adoptive transfer of allogeneic immune cells for the treatment of malignant blood disorders such as leukemia and lymphoma. This comprises both hematopoietic stem cell transplantation and innovative cell therapy approaches such as the transfer of chimeric-antigen-receptor (CAR) modified immune cells. Central areas of investigation regard the processing and presentation of antigenic peptides by human leukocyte antigen (HLA) molecules and their recognition by the T cell receptor (TCR), both in-vitro and ex-vivo in patients after allogeneic cell therapy. Moreover, mechanisms of tumor immune evasion and the interaction between tumor- and virus-specific T cells are being investigated. Methodologically, the projects rely on a wide array of innovative experimental platforms in cell culture (ie, mass spectrometry of the HLA immunopeptidome) and molecular biology (ie, Next Generation Sequencing of the TCR).